Faricimab treatment study for wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study observes how a drug called faricimab works in treating wet AMD (a condition affecting central vision in older adults). You would receive four initial injections into your eye, then additional injections as needed based on your response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 or older
- Diagnosis of wet AMD in one eye with fluid buildup affecting your central vision, confirmed by eye imaging
- Current vision between 20/32 and 20/320 on standard eye chart test
- Have not received any previous AMD treatments (injections, steroids, or laser therapy)
- Clear enough eye structures to allow proper examination and imaging
- Willing to receive faricimab injections and attend follow-up visits for at least several months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.
This study tests a combination of standard eye injections and laser treatment for wet age-related macular degeneration, a condition where abnormal blood vessels leak fluid and harm vision. It aims to see if this combined approach is safe and effective, potentially reducing the number of injections needed.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.